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Mutations in the HIV-1 proviral genomes delay the progression of the disease. We compared the
mutation status in full-length proviral genomes of 23 HIV-infected patients with undetectable viral loads
in the absence of therapy named natural viral suppressors (NVS) or Elite Controllers with 23 HIV-infected
controls (10 patients on HAART treatment and 13 untreated patients). Provirus DNA was extracted from
PBMC for ampliﬁcation and sequencing to determine the mutation status. Nine (39 %) of the 23 NVS
patients had defective proviral genomes, compared to 4 of the treated controls (40%, p¼0.96) and only
one of the untreated controls (8%, p¼0.059). Most of the defective genomes resulted from Gto-A
hypermutation. Among patients with hypermutation, the rate ratio for mutation was signiﬁcantly higher
for the NVS compared to treated controls (p¼0.043). Our data suggests that inactivation of the virus
through the APOBEC3G system may contribute to the NVS phenotype.
& 2013 Elsevier Inc. All rights reserved.Introduction
In recent years, there have been important advances in the
understanding of innate immunity and the role it plays in the
control of HIV-1 infection. Various patterns of disease progression
have been associated with host genetics, immunological and
virological factors (Grabar et al., 2009; Okulicz et al., 2009).
A subset of HIV-infected patients who are able to suppress
circulating virus naturally, without the use of anti-retroviral drugs,
have been studied extensively. Often referred to as “Elite Con-
trollers” or “Elite Suppressors,” these individuals have very low to
undetectable plasma HIV-1 RNA levels and relatively normal CD4+
T-cell counts (Wang et al., 2003; Walker, 2007; Sajadi et al., 2007;
Blankson et al., 2007). In our Baltimore patient population, this
phenotype is present in 1.5% of all HIV-1 seropositive individuals
and they are referred to as “natural viral suppressors”, or “NVS”
(Sajadi et al., 2009). Thus far there has been an intensive effort by
us and others to identify the mechanisms by which these indivi-
duals suppress their virus and multiple host factors have been
identiﬁed (Okulicz et al., 2009; Hunt, 2009; Salgado et al., 2010;
Baker et al., 2009; Blankson, 2010).ll rights reserved.
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.M. Eyzaguirre).In addition to host factors, viral factors that might be associated
with the NVS phenotype have been investigated. In a recent study,
viruses from controllers displayed signiﬁcantly lower replication
capacity compared to those from progressors (po0.0001)
(Brumme et al., 2011). Others suggest that inhibitory mutations
in vpr, nef, and rev could be associated with the NVS phenotype
(Lum et al., 2003; Mologni et al., 2006; Iversen et al., 1995; Malim
et al., 1991; Wang et al., 2003; Tolstrup et al., 2006; Caly et al.,
2008). It has also been suggested that some individuals are
infected with virions that are less capable of evading the host
immunological response or are impaired. One common cause of
impairment is due to viral genomes that contain APOBEC3G (A3G)
or APOEC3F (A3F) induced hypermutation (Wang et al., 2003;
Sandonis et al., 2009; Gandhi et al., 2008). In addition, mutations
in epitopes for B27, B57, B58 recognition and the number of
NFkappaB sites have also been correlated with long-term control
(Migueles et al., 2000; Bailey et al., 2007; Goulder et al., 2001).
The current study investigates this unique group of NVS
individuals to test the hypothesis that durable viral suppression
may be caused in part by viral inactivation. Using both partial and
full genome sequencing, others have found no signiﬁcant muta-
tions or deletions in the viruses with which these patients are
infected (Blankson et al., 2007; Gandhi et al., 2008). This study
presents 23 nearly full genome sequences of NVS patients, span-
ning most of the viral genome, for examination and comparison
with genomes from two control groups. The control groups consist
of 10 patients with undetectable viral loads on HAART treatment
and 13 untreated patients with detectable viral loads.
Table 1
Characteristics of NVS patients, controls on HAART, and untreated controls.
^Fisher Exact p-value where less than 0.05 is indicative of a hypermutant. The APOBEC Ratio is deﬁned as all GG and GA substitutions compared to all GC and CT substitutions. Analysis of all genes: color grey shows defective due to
hypermutation; orange defective due to incorrect start amino acid and hypermutation, yellow defective due to incorrect start amino acid, blue defective due to deletion/frameshift, red defective due to frameshift, incorrect starting
codon and hypermutation.
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The NVS group consisting of 23 patients were 57% males, all
African American, between the ages of 30 and 62 (mean 49.6; SD
9.1), with injecting drug use (IDU) as the main risk factor (57%),
and viral loads ranging from o40 to 475 copies/mL. The control
group on HAART consisting of 10 patients were 80% males, mostly
African American (80%), between the ages of 27 and 52 years old
(mean 39.5; SD 10.0), with heterosexual sex as their main risk
factor (90%), and viral loads of less than 50 copies/mL. The
treatment naïve controls consisting of 13 patients were 62% males,
all African American, between the ages of 30 and 58 (mean 42.4;
SD 9.0), with IDU as their main risk factor, and viral loads ranging
from 2630 to 4750,000 copies/mL (Table 1). Phylogenetic analysis
of all 46 nearly full-length proviral genomes along with reference
subtypes showed that all NVS all control are infected with subtype B,
HIV-1 virus (phylogenetic tree not shown). A visual representation
of the NVS samples, the controls, reference for subtype B (Ref.B.
MN.M17449, Ref.B.FR.83.HXB2, and Ref.B.US.AY331295) is shown in
Fig. 1 where it can be observed that two control samples (07US.SAJ.
C162.H2 and 06US.SAJ.C167.LH) are phylogenetically linked. No known
epidemiological linkage was identiﬁed: both were female subjects
who reported heterosexual sex as their risk factor.
From the nearly full-length sequences, we deﬁned defective
proviral genomes as having signiﬁcant hypermutation rate ratio or
having defective genes. Nine (39%) of 23 NVS patients had clearly
defective proviral genomes based on sequence, compared to four
(40%) from the control group on treatment (p¼0.96) and only 1Fig. 1. Phylogenetic tree of non-hypermutated HIV-1 near-full length sequences. NVS sam
squares), and the reference sequences (Ref.B.MN.M17449, Ref.B.FR.83.HXB2, and Ref.B.
sequences and is based on neighbor joining method. They were constructed using MEG(8%) from the untreated control group (p¼0.059). Most of the
defective proviral genomes (78.6%) resulted from G-to-A hyper-
mutation. There were no differences in the proportion of patients
with hypermutations between NVS (26%), treated controls (40%),
and untreated controls (8%). However, among patients that did
have hypermutations, the median rate ratio for hypermutation was
signiﬁcantly higher for NVS compared to treated controls (4.87 vs.
3.11, Wilcoxon’s two sample test p¼0.043, respectively). The mean
values of the hypermutation rate ratio were also comparable to the
median values and were also signiﬁcantly different between the
two groups (4.84 vs. 3.07, p¼0.029, respectively). Overall, the
majority of the hypermutated genomes observed in all three
groups were in an APOBEC3G context (G-to-A mutations in a GG
context) with a hypermutation ratio ranging from 2.09 to 7.04
(Table 1).
In addition to hypermutation, proviruses were also defective
due to frame shifts, incorrect start codons, and deletions. In the
NVS group, all six hypermutated samples had incorrect start
codons in several genes (ATG to ATA) and two of them also had
frameshift mutations in the nef gene. Additionally, the NVS group
included three samples that were clearly defective based on
sequence alone; they had signiﬁcant deletions that caused frame-
shifts in essential genes (Table 1). The controls on HAART also
showed similar defects: all four hypermutated samples had
incorrect start codons at different genes and two of them also
had frameshifts in the nef gene. The one untreated control that
was hypermutated had an incorrect start codon in the nef gene;
however, about 44% of the genome was not hypermuted and it hadples (blue squares), controls on HAART (green squares), untreated controls (orange
US.AY331295). The phylogenetic analysis has been performed on near-full length
A3 (Kumar et al., 2004; Saitou and Nei, 1987).
Fig. 2. Levels of hypermutation in HIV-1 proviral genomes using the APOBEC Ratio. (A) Hypermutation ratio of NVS patients, (B) hypermutation ratio of controls on HAART,
and (C) hypermutation ratio of untreated controls. The APOBEC Ratio is deﬁned as all GG and GA substitutions compared to all GC and CT substitutions.
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samples (Fig. 2). In this paper, we deﬁne APOBEC Ratio as the total
sum of the GG to GA substitutions, which are caused by APOBEC3
activity, in relation to GC to GT substitutions, which are back-
ground mutations. Hypermutation throughout the genomes of
both control groups was notably lower than the NVS group, as can
be observed on Table 1: not all genes were hypermutated. The
naïve control group had the least number of hypermutated genes
compared to the NVS group (mean number of 0.4 vs. 2.4,
respectively, p¼0.03). There was no difference in the mean
number of hypermutated genes between naïve controls and
controls on HAART. The degree of hypermutation can also be
observed in Fig. 2: the mean APOBEC Ratio for the NVS group was
3.1 (SD, 3.0). The untreated controls had signiﬁcantly lower
APOBEC ratios than the NVS group (mean ratio of 1.7 vs. 3.1,
respectively, p¼0.04) but marginally lower when compared to the
controls on HAART (mean ratio of 1.7 vs. 2.8, respectively, p¼0.09).
In the literature, various mutations have been identiﬁed and
associated with the long term non-progressors phenotype
(Poropatich and Sullivan, 2011; O’Connell et al., 2010; Bailey
et al., 2007; Deeks and Barre-Sinoussi, 2012). The following such
mutations were found not to be associated with the NVS pheno-
type in this study: vpr R77Q and F72L, rev L78I, and nef T138Q. The
number of NF-kappaB sites was not signiﬁcantly different between
the groups. Epitopes recognized by HLA Type I haplotypes, B27,
B57 and B58, were identiﬁed in the NVS group but there was no
signiﬁcant enrichment for these. The diversity of envwas analyzed,
speciﬁcally the length and potential N-linked glycosylation sites of
the V1–V2 loop and they were not found to be signiﬁcantly
different between the groups (Mens et al., 2010). Analysis of the
pairwise genetic distances in each population revealed that theNVS patients’ pairwise genetic distance over the entire genome
was 7.0% (7 0.002%) compared to 9.2% (7 0.002%) among the
controls. No signiﬁcant differences were identiﬁed between the
two control groups.Discussion
The use of nearly full genome sequencing enabled the entire
HIV genome to be characterized; therefore, defective viruses of
multiple types could be detected. In this study, the NVS group had
more defective genomes than the untreated HIV cohort, while no
difference was seen between the NVS and the control group on
HAART. However, the degree of hypermutation was much greater
in the NVS than the two control groups.
In the human host, the gene apolipoprotein B mRNA-editing
enzyme catalytic polypeptide-like editing complex 3 (APOBEC3)
speciﬁcally targets retroviruses. This family of cytidine deami-
nases, speciﬁcally APOBEC3G (A3G) and APOBEC3F (A3F), was
previously found to be responsible for hypermutation in HIV-1
(Harris and Liddament, 2004; Lecossier et al., 2003). In the absence
of virally encoded virus infectivity factor (Vif), the A3G protein is
incorporated into virions and causes hypermutation usually during
reverse transcription of the genome (Liu et al., 2005). Defective
viral genomes result from this, due to GG-to-GA mutations of the
HIV-1 proviral DNA (Liu et al., 2005). Via a similar mechanism, A3F
mediates GA-to-AA mutations but at a rate that is 10 times lower
than that of A3G (Liu et al., 2005; Holmes et al., 2007).
Individuals able to control virus, whether by treatment or
without, have a higher proportion of the proviral genomes that
are defective. In chronic HIV infection, the proviral reservoir,
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of newly infected versus dying cells, each of which may harbor
defective or functional provirus. Previous studies have shown that
patients harboring hypermutated sequence had viral loads sig-
niﬁcantly lower than those with nonhypermutated sequence (Pace
et al., 2006).
In this study, 40% of HAART treated controls and 26% of NVS
had evidence of hypermutation compared to 8% (or one) of the
controls not on treatment. Even this one untreated control may be
an exception: this individual not only had a relatively low viral
load (2630 copies/mL) but was also infected with a virus that had a
lower hypermutation rate ratio, lower APOBEC ratio, and about
half of the genes analyzed were not hypermutated. The ﬁnding of a
higher rate of defective viruses in patients with lower viral load
suggests that the ratio of defective to functional proviruses
increases when the viral load is lowered by therapy or the host
immune system.
Although patients with low viral load (NVS or HAART treated)
have a higher degree of hypermutation than naïve controls, the
level of hypermutation was signiﬁcantly higher in the NVS
compared to the HAART group. The degree of hypermutation
observed in the NVS samples and their low genetic diversity
suggests that one possible mechanism for this phenotype is
inactivation of the virus at initial infection by blocking HIV-1
replication directly or through inactivation by hypermutation.
Interestingly, while patients similar to the NVS are known to
have higher viral loads than HAART treated patients (Hatano et al.,
2009), in this study NVS individuals had more defective genomes
than the treated controls (Table 1). Although this result was not
statistically signiﬁcant, it suggests that the number of circulating
virus may not be the only factor affecting the prevalence of
defective viruses, and other factors such as length of HIV infection,
duration of therapy/viral control may also be important. In addi-
tion, for individual NVS patients, either infected with a defective
virus or with strong host immunity may lead to the observation of
frequent defective genomes.
One limitation of our study is that our technique of DNA extraction
includes both integrated and unintegrated DNA. Although Elite Con-
trollers have been shown to have large amounts of unintegrated DNA
compared to integrated DNA (Graf et al., 2011; Buzon et al., 2011)
mutations into the genome occur at reverse transcription (before this
stage). Post-reverse transcription mutations are known to occur at the
junction of the 2-LTR circle (Whitcomb et al., 1990; Pauza, 1990), but
this would have no bearing on env, gag, and pol. Furthermore, it has
been shown that sequences derived from PBMC-DNA (integrated and
unintegrated) are phylogenetically similar to sequences derived from
cell-free virus in serum (unintegrated) when obtained from the same
time point (Edo-Matas et al., 2010). Another limitation to our study is
the number of NVS patients and the number of sequences analyzed.
Patients who are able to suppress circulating virus naturally are rare;
thus, establishing a cohort with a large number of these unique
subjects is very difﬁcult. The very low number of HIV-1 proviral DNA
in the NVS patients is an obstacle in obtaining full-genome ampliﬁca-
tion. It has been reported that the lower boundary for full-genome
ampliﬁcation is around 300 proviral DNA copies per PCR reaction
(Simmonds et al., 1990b). The proviral DNA previously reported in our
NVS patients ranges from 1 to 74 copies per 10\widehat6 PBMC (Sajadi
et al., 2007). Thus, the NVS patients in our study had such small
quantities of proviral DNA that prevented us from replicating studies
where they ran large number of PCR reactions per sample such is the
case of single-genome ampliﬁcation. The single-genome ampliﬁcation
method is widely used to identify founder viruses and viral popula-
tions. Using this method DNA is titrated by end-point dilutionwhere a
DNA concentration yields no more than 30% positive PCRs this is
conformed to a Poisson distributionwhere a single template is present
per reaction (Keele et al., 2008; Salazar-Gonzalez et al., 2008, 2011;Simmonds et al., 1990a). As mentioned above we were restricted to
smaller number of PCR reactions since our target (9000 kb fragment)
requires more DNA than PCR of small fragments. However, only about
1–2% of all reactions performed per sample resulted in a positive PCR.
Due to the complexity of amplifying a 9000 base fragment and the
1–2% positive PCR success rate our sequences should be representative
of the provirus population within each patient sample.Method
Study subjects
The enrollment and data collection procedures for subjects in
this prospective study have been described in detail elsewhere
(Sajadi et al., 2007, 2009). Brieﬂy, the case deﬁnition is as follows:
patients must be drug naïve, be conﬁrmed HIV-1 positive by
Western blot and proviral DNA, and have viral loads of o400
copies per milliliter for a minimum 2-year period (one viral load
4400 copies/mL in a 2-year period was allowed). The median of
years of HIV-1 viral suppression was 6.7 (Sajadi et al., 2009). Two
control groups of HIV-1 infected individuals were selected. One
group had undetectable viral loads and was on HAART treatment
(n¼10) while the other had detectable viral loads and was
treatment naïve (n¼13). This study had IRB approval, and all
individuals provided informed consent.
Extraction, ampliﬁcation and sequencing
Peripheral blood mononuclear cells (PBMCs) from NVS were
obtained. The cells were separated by the Ficoll–Hypaque techni-
que and were used for DNA extraction by the QIAmp DNA
extraction kit (QIAgen, Valencia, CA, USA). Due to the small
quantity of proviral DNA in some of the samples, minor changes
were made to the manufacturer QIAmp DNA extraction protocol.
The extracted DNA was reconstituted in 40 mL of Buffer AE that
was diluted in water (1:4) instead of the directed 200 mL. To
further concentrate the extracted proviral DNA the 40 mL of DNA
were reduced to ∼10 mL using a speed vacuum. Using limiting
template dilution nearly full-length proviral genomes (about
9000 kb) were ampliﬁed. Multiple reactions were carried out to
achieve an end-point dilution with a positive PCR following
previously described methods (Salminen et al., 1995; Carr et al.,
1996, 2001 Arroyo et al., 2004). To minimize the chances of
producing heterogeneous DNA targets and approximate ampliﬁca-
tion of a single copy of the target DNA the lowest possible dilution
template was used in the ﬁrst round PCR. Furthermore, to over-
come the problem of amplifying rare templates sequences nested
primers (internal primers) were used to ensure that only the
targeted sequences were further ampliﬁed (Simmonds et al.,
1990b). Primers MSF12/OFMR1 were used for the ﬁrst round
primers and F2NST/UNINEF7 were used as the internal primers
in a second-round ampliﬁcation (Salminen et al., 1995; Carr et al.,
2001; Arroyo et al., 2004). The potential recombination between
DNA were addressed by using PCR conditions with an increased
elongation time and using the lowest possible number of PCR
cycles (Meyerhans et al., 1990; Judo et al., 1998). These fragments
were then sequenced with Big Dye terminators using an ABI 3130
automated sequencer (Applied Biosystems Inc, Foster City CA), as
previously described (Carr et al., 2001).
Analysis
Sequences were analyzed, edited, and assembled with
Sequencher 3.0 (Ann Arbor, MI). All genes were analyzed for open
reading frames and hypermutation was assessed using the
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non-hypermutated reference isolate Ref.B.MN.M17449 (Accession
number M17449). The rate ratio used in HYPERMUT software is
deﬁned as the number of nucleotide guanine (G) to adenine
(A) substitutions divided by the number of adenine (A) to guanine
(G) substitutions, adjusting for the adenine-rich nature of the HIV
genome. In order to only quantify the substitutions caused by
APOBEC3 activity we compared the total sum of the GG to GA
substitutions compared to GC to GT substitutions, which are
background mutations. This value provided us with a degree of
hypermutation that we refer to as the APOBEC ratio. Phylogenetic
analysis was performed by aligning the sequences obtained with
reference sequences using the program MacGDE (Linton) followed
by a Neighbor-joining method with Kimura’s two-parameter
model of distance calculation; bootstrap analysis was performed
with 100 replicas. Phylogenetic trees were constructed using
MEGA3 (Kumar et al., 2004; Saitou and Nei, 1987). In addition,
the program SimPlot v.3.5.1 was used to explore recombination
events on all sequences obtained (Lole et al., 1999). Point muta-
tions associated with long term non-progressors found in the
literature were sought and their signiﬁcance was determined
using ﬁsher’s exact test for categorical comparisons. Major muta-
tions that have been associated with reduced susceptibility to
protease and RT inhibitors were analyzed using the Stanford
University HIV Drug Resistance Database: this online tool gener-
ated a genotypic antiretroviral drug resistance proﬁle (Rhee et al.,
2003; Shafer, 2006 Liu and Shafer, 2006). All sequences have been
submitted to GenBank and can be found under accession numbers
JF689852 to JF689897.Conclusion
The current data, in which the NVS patients have higher
hypermutation rate ratios than the controls, supports the hypoth-
esis that their viruses were more heavily hypermutated by the
ABOBEC3G system than viruses in the controls. It is clear that there
are conﬂicting results about the types and the frequencies of
mutations in non-progressors; thus, more research needs to be
done to study the viral populations within each infected indivi-
dual. Future studies could include performing pyrosequencing to
fully understand the virological diversity and identifying genetic
polymorphisms in the APOBEC3G gene (∼10 kb) of the NVS
subjects to identify factors that contribute to the NVS ability to
suppress their infection naturally.Authors’ contributions
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